In terms of the molecular mechanisms of molecular this combination therapy, we found that TNFR2 levels correlated positively with PD-L1 levels, and TNFR2 could regulate PD-L1 expression in pancreatic cancer in vitro and in vivo. This evidence concerns the gene CD274 and familial pancreatic carcinoma.